介孔生物活性玻璃装载和释放抗癌药物表阿霉素的研究

doi:10.3724/SP.J.1077.2011.00068

无机材料学报 ›› 2011, Vol. 26 ›› Issue (1): 68-72.DOI: 10.3724/SP.J.1077.2011.00068 CSTR: 32189.14.SP.J.1077.2011.00068

介孔生物活性玻璃装载和释放抗癌药物表阿霉素的研究

周艳玲, 冯新星, 翟万银, 常江

中国科学院上海硅酸盐研究所, 上海 200050

收稿日期:2010-04-10 修回日期:2010-05-21 出版日期:2011-01-20 网络出版日期:2010-12-23
作者简介:周艳玲(1983-), 女, 硕士研究生. E-mail: cherry@mail.sic.ac.cn
基金资助:
国家重点基础研究发展973计划(2005CB522704); 国家自然科学基金(30730034); 上海市基础研究重点项目(08JC1420800); 国家高技术研究发展863计划(2007AA03Z317)

Study on the Loading and Releasing Behavior of EpirubicinHydrochloride from Mesoporous Bioactive Glasses (MBGs)

ZHOU Yan-Ling, FENG Xin-Xing, ZHAI Wan-Yin, CHANG Jiang

Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai 200050, China

Received:2010-04-10 Revised:2010-05-21 Published:2011-01-20 Online:2010-12-23
Supported by:
973 Program (2005CB522704); National NatureScience Foundation of China(30730034); Shanghai Basic Research Project (08JC1420800); 863 Program(2007AA03Z317)

摘要/Abstract

摘要： 将介孔58S生物活性玻璃(m58S)作为抗癌药物载体评价了其对表阿霉素的装载量和释放性能. 实验结果表明, m58S对亲水性药物表阿霉素的药物装载量为40%, 是普通溶胶-凝胶58S生物活性玻璃的3倍多, 并且具有更长效的缓释特性. 研究还发现释放介质的pH值对表阿霉素的释放速率有很大影响, pH值越低, 表阿霉素分子从载体材料中释放出的速率越快. 因此, 介孔生物活性玻璃是一种高效的药物缓释载体, 且药物释放速率受释放介质pH值影响, 有望成为药物控释型骨修复材料.

关键词: 生物活性玻璃, 介孔材料, 药物载体

Abstract: Mesoporousbioactive glasses m58S were loaded with an anticancer drug-Epirubicin hydrochloride(EPI) and the release of the drug from the glasses was evaluated. The drugloading capacity of m58S for EPI was 40%, which was three times higher thanthat of conventional Sol-Gel bioactive glasses 58S. In phosphate buffered saline (PBS), the m58S-EPI system showed asustained release behavior. Furthermore, the release rates from the EPI-m58Ssystem increased with the decrease of pH values of the release medium. Theresults suggest that m58S is an effective anticancer drug carrier and itspH-related release behavior suggests that it has potential for design ofcontrolled drug delivery bone grafting materials.

Key words: bioactive glasses, mesoporous materials, drug delivery system

中图分类号:

R318

周艳玲, 冯新星, 翟万银, 常江. 介孔生物活性玻璃装载和释放抗癌药物表阿霉素的研究[J]. 无机材料学报, 2011, 26(1): 68-72.

ZHOU Yan-Ling, FENG Xin-Xing, ZHAI Wan-Yin, CHANG Jiang. Study on the Loading and Releasing Behavior of EpirubicinHydrochloride from Mesoporous Bioactive Glasses (MBGs)[J]. Journal of Inorganic Materials, 2011, 26(1): 68-72.

参考文献

[1] Wang T W, Wu H C, Wang WR, et al. The development of magneticdegradable DP-bioglass for hyperthermia cancer therapy. J. Biomed. Mater. Res. B, 2007, 83A: 828-837.
[2] Geraci M, Birch J M,Alston R D, et al. Cancer mortalityin 13 to 29-year-olds in England and Wales, 1981-2005. Br. J. Cancer, 2007, 97: 1588-1594.
[3] Schulman K L, Kohles J.Economic burden of metastatic bone disease in the US. Cancer, 2007, 109(11): 2334-2342.
[4] Anderson P,Salazar-Abshire M. Improving outcomes in difficult bone cancers usingmultimodality therapy, including radiation: physician and nursing perspectives.Curr. Oncol. Rep., 2006, 8(6): 415-422.
[5] Arndt C A S, Crist W M.Medical progress-common musculoskeletal tumors of childhood and adolescence. New. Eng. J. Med., 1999, 341(5): 342-352.
[6] MarinaN, Gebhardt M, Teot L, et al. Biologyand therapeutic advances for pediatric osteosarcoma. Oncologist, 2004, 9(4):422-441.
[7] Sandberg A A, Bridge J A.Updates on the cytogenetics and molecular genetics of bone and soft tissuetumors: osteosarcoma and related tumors. CancerGenet. Cytogen., 2003, 145(1): 1-30.
[8] BagiC M. Targeting oftherapeutic agents to bone to treat metastatic cancer. Adv. Drug Delivery Rev., 2005, 57(7):995-1010.
[9] Guise T A, Mundy G R. Cancerand bone. Endocr. Rev., 1998, 19(1): 18-54.
[10]Nagarajan R, Clohisy D R, Neglia J P, et al. Function and quality-of-life of survivors of pelvic andlower extremity osteosarcoma and Ewing's sarcoma: the childhood cancer survivorstudy. Br. J. Cancer, 2004, 91(11): 1858-1865.
[11]Meyer J S, Mackenzie W. Malignant bone tumors andlimb-salvage surgery in children. Pediatr.Radiol., 2004, 34(8): 606-613.
[12]Felder-Puig R, Formann A K, Mildner A, et al. Quality of life and psychosocial adjustment of youngpatients after treatment of bone cancer. Cancer,1998, 83(1): 69-75.
[13]Serrano M C, Portoles M T, Pagani R, et al. <>In vitro positive biocompatibility evaluation ofglass-glass ceramic thermoseeds for hyperthermic treatment of bone tumors. Tissue Eng. A, 2008, 14(5): 617-627.
[14]Lindfors N C, Heikkila J T, Aho A J. Long-term evaluation ofblood silicon and ostecalcin in operatively treated patients with benign bonetumors using bioactive glass and autogenous bone. J. Biomed. Mater. Res. B, 2008, 87B(1): 73-76.
[15]Takegami K, Sano T, Wakabayashi H, et al. New ferromagnetic bone cement for local hyperthermia. J. Biomed. Mater. Res., 1998, 43(2): 210-214.
[16]Hench L L. Bioceramics. J. Am. Ceram. Soc., 1998, 81(7):1705-1728.
[17]Hench L L. Bioceramics-from concept to clinic. J. Am. Ceram. Soc., 1991, 74(7): 1487-1510.
[18]Yan X X, Yu C Z, Zhou X F,et al. Highly ordered mesoporous bioactive glasses with superior in vitrobone-forming bioactivities. Angew. Chem. Int.Ed, 2004, 43(44): 5980-5984.
[19]Xia W, Chang J. Well-ordered mesoporous bioactiveglasses (MBG): A promising bioactive drug delivery system. J. Controlled Release, 2006, 110(3):522-530.
[20]Xia W, Chang J, Lin J P, etal. The pH-controlled dual-drug release from mesoporous bioactiveglass/polypeptide graft copolymer nanomicelle composites. Eur. J. Pharm. Biopharm, 2008, 69(2): 546-552.
[21]Xia W, Chang J. Preparation, <>in vitrobioactivity and drug release property of well-ordered mesoporous 58S bioactiveglass. J. Non-Cryst. Solids, 2008, 354(12/13): 1338-1341.
[22]Kumar D, Tomar R S, Deolia S K, et al. Isolation and characterization of degradation impurities inepirubicin hydrochloride injection. J. Chromatogr.B, 2008, 869(1/2): 45-53.
[23]Ozdemir F A, Anilanmert B, Pekin M. Spectrophotometricinvestigation of the chemical compatibility of the anticancer drugsirinotecan-HCI and epirubicin-HCI in the same infusion solution. Cancer Chemoth. Pharm, 2005, 56(5): 529-534.
[24]Kelso E J, Geraghty R F, McDermott B J, et al. Characterisation of a cellular model of cardiomyopathy, inthe rabbit, produced by chronic administration of the anthracycline,epirubicin. J. Mol. Cell Cardiol.,1997, 29(12): 3385-3397.
[25]Masuda N, Amani S, Nishikata M, et al. Appropriate solution selection at the administeringepirubicin hydrochloride to the breast cancer patients. <>European Journal ofCancer Supplements, 2004, 2(3):145.
[26]Nielsen O S, Dombernowsky P, Mouridsen H, et al. High-dose epirubicin is not analternative to standard-dose doxorubicin in the treatment of advanced softtissue sarcomas. a study of the EORTC soft tissue and bone sarcoma group. Br. J. Cancer, 1998, 78(12): 1634-1639.
[27]刘勤江, 田尤新, 肖忆南. 阿霉素在肿瘤局部化疗中的应用研究.肿瘤学杂志, 2004, 10(1): 45-47.
[28]Oonishi H, Kushitani S, Yasukawa E, et al. Particulate bioglass compared with hydroxyapatite as a bonegraft substitute. Clin. Orthop. Relat.Res., 1997, 334: 316-325.
[29]Oonishi H, Hench L L, Wilson J, et al. Comparative bone growth behavior in granules of bioceramicmaterials of various sizes. J. Biomed.Mater. Res., 1999, 44(1): 31-43.
[30]Zhong J P, Greenspan D C. Processing and propertiesof Sol-Gel bioactive glasses. J. Biomed.Mater. Res., 2000, 53(6): 694-701.
[31]Chen Q Z, Ahmed I, Knowles J C, et al. Collagen release kinetics of surface functionalized 4555Bioglass^®-based porous scaffolds. J. Biomed. Mater. Res. A, 2008, 86A(4): 987-995.
[32]Erdinc N, Gokturk S, Tuncay W. Interaction of epirubicinHCl with surfactants: effect of NaCl and glucose. J. Pharm. Sci., 2004, 93(6):1566-1576.
[33]Li X, Zhang L X, Dong X P, <>et al. Preparation of mesoporous calcium doped silica spheres withnarrow size dispersion and their drug loading and degradation behavior. Microporous. Mesoporous. Mater., 2007, 102(1/2/3): 151-158.
[34]Zhao D Y, Feng J L, Huo Q S, et al. Triblock copolymer syntheses of mesoporous silica withperiodic 50 to 300 angstrom pores.Science, 1998, 279(5350): 548-552.
[35]Guo M, Yan Y, Zhang H K,et al. Magnetic and pH-responsive nanocarriers with multilayer core-shellarchitecture of anticancer drug delivery. J.Mater. Chem., 2008, 18(42): 5104-5112.
[36]Pal R, Kundu D. Sol-Gel synthesis of porous anddense silica microspheres. J. Non-Cryst.Solids, 2009, 355(1): 76-78.

介孔生物活性玻璃装载和释放抗癌药物表阿霉素的研究

Study on the Loading and Releasing Behavior of EpirubicinHydrochloride from Mesoporous Bioactive Glasses (MBGs)

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	吴锐, 张敏慧, 金成韵, 林健, 王德平. 光热核壳TiN@硼硅酸盐生物玻璃纳米颗粒的降解和矿化性能[J]. 无机材料学报, 2023, 38(6): 708-716.
[2]	庞力斌, 王德平. 介孔硼硅酸盐玻璃微球药物载体的制备及其性能表征[J]. 无机材料学报, 2022, 37(7): 780-786.
[3]	唐洁吟, 王刚, 刘聪, 邹学农, 陈晓峰. 微纳米生物活性玻璃诱导牙本质再矿化研究[J]. 无机材料学报, 2022, 37(4): 436-444.
[4]	施吉翔, 翟东, 朱敏, 朱钰方. 生物活性玻璃-二氧化锰复合支架的制备与表征[J]. 无机材料学报, 2022, 37(4): 427-435.
[5]	陈铖, 丁晶鑫, 王会, 王德平. 掺钕介孔硼硅酸盐生物活性玻璃陶瓷骨水泥的制备与性能表征[J]. 无机材料学报, 2022, 37(11): 1245-1258.
[6]	朱子旻, 张敏慧, 张轩宇, 姚爱华, 林健, 王德平. 硼硅酸盐生物活性玻璃在直流电场下的体外矿化性能[J]. 无机材料学报, 2021, 36(9): 1006-1012.
[7]	林子扬, 常宇辰, 吴章凡, 包荣, 林文庆, 王德平. 不同模拟体液对硼硅酸盐生物活性玻璃基骨水泥矿化性能的影响[J]. 无机材料学报, 2021, 36(7): 745-752.
[8]	黄谢意,王鹏,尹国恒,张绍宁,赵伟,王东,毕庆员,黄富强. 掺磷非晶氧化钛负载铂用于高效催化氧化挥发性有机化合物[J]. 无机材料学报, 2020, 35(4): 482-490.
[9]	程福强,吉田田,薛敏,孟子晖,吴玉凯. 巯基改性SBA-15的制备及其对Cr⁶⁺的吸附[J]. 无机材料学报, 2020, 35(2): 193-198.
[10]	常宇辰, 林子扬, 谢昕, 吴章凡, 姚爱华, 叶松, 林健, 王德平, 崔旭. 基于介孔硼硅酸盐生物活性玻璃微球的可注射复合骨水泥[J]. 无机材料学报, 2020, 35(12): 1398-1406.
[11]	马芳, 崔名芳, 朱建华, 李雅丽. 聚烯丙基氯化铵调控下多孔羟基磷灰石微球的合成及作为药物载体的应用研究[J]. 无机材料学报, 2017, 32(11): 1215-1222.
[12]	罗维, 魏晶, 邓勇辉, 李宇慧, 王连军, 赵涛, 江莞. 新型两亲性嵌段共聚物导向合成有序大孔径介孔材料的研究进展[J]. 无机材料学报, 2017, 32(1): 1-10.
[13]	翟丽丽, 张江, 李轩科, 丛野, 董志军, 袁观明. 模板剂F127对介孔SnO₂的孔结构及电化学性能的影响[J]. 无机材料学报, 2016, 31(6): 588-596.
[14]	朱开平, 孙静, 叶松, 周杰, 王会, 王德平. 新型中空羟基磷灰石微球/壳聚糖复合药物载体用于药物控制释放[J]. 无机材料学报, 2016, 31(4): 434-442.
[15]	董志红, 聂志萍, 周长春. 自然唾液中介孔生物活性玻璃诱导牙釉质仿生再矿化研究[J]. 无机材料学报, 2016, 31(1): 88-94.